Veracyte, Inc. (VCYT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Veracyte, Inc. (VCYT) Healthcare & Pipeline Overview

Veracyte, Inc. is a global diagnostics company specializing in genomic sequencing classifiers and assays for cancer and pulmonary diseases, providing actionable insights for physicians and patients. Their focus on reducing unnecessary surgeries and informing treatment decisions positions them as a key player in precision medicine.

What Is the Investment Thesis for VCYT?

Veracyte, Inc. presents a notable research candidate within the diagnostics sector. With a market capitalization of $4.55B and a P/E ratio of 39.6, the company demonstrates strong profitability, supported by a 16.2% profit margin and a 71.4% gross margin. Growth catalysts include the continued adoption of its existing diagnostic tests and the successful development and commercialization of new products like the Percepta Genomic Atlas and LymphMark. The company's strategic collaborations with Johnson & Johnson, Acerta Pharma, and CareDx provide additional avenues for expansion and innovation. However, potential risks include competition from other diagnostics companies and the uncertainty associated with regulatory approvals for new products. The company's high beta of 1.96 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

VCYT Key Highlights

• Market Cap of $4.55B reflects investor confidence in Veracyte's growth potential and market position.
• P/E ratio of 39.6 indicates a premium valuation, suggesting expectations of future earnings growth.
• Profit Margin of 16.2% demonstrates efficient operations and strong pricing power within the diagnostics market.
• Gross Margin of 71.4% highlights the value-added nature of Veracyte's genomic testing services.
• The company has strategic collaborations with Johnson & Johnson, Acerta Pharma, and CareDx, expanding its reach and capabilities in the diagnostics market.

Who Are VCYT's Competitors?

VCYT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VCYT's Key Strengths?

• Proprietary genomic technologies and intellectual property.
• Clinically validated diagnostic tests with proven accuracy.
• Strategic collaborations with leading pharmaceutical and diagnostic companies.
• Established market presence and strong reputation in the diagnostics industry.

What Are VCYT's Weaknesses?

• Reliance on a limited number of key products.
• Potential for competition from larger, more established diagnostic companies.
• Dependence on regulatory approvals for new products.
• High beta value indicates higher volatility compared to the market.

What Could Drive VCYT Stock Higher?

• Potential regulatory approvals for new diagnostic tests, such as the Percepta Genomic Atlas and LymphMark.
• Continued adoption of existing diagnostic tests, driving revenue growth.
• Strategic collaborations with pharmaceutical companies, expanding market reach and product development opportunities.

What Are the Key Risks for VCYT?

• Rich valuation — a P/E of 39.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Competition from other diagnostic companies, potentially impacting market share.
• Changes in regulatory requirements and reimbursement policies, affecting profitability.
• Dependence on key products, making the company vulnerable to market shifts.
• High beta value indicates higher volatility compared to the market.

What Are the Growth Opportunities for VCYT?

• Expansion of the Percepta Platform: Veracyte is developing the Percepta Genomic Atlas to help inform lung cancer treatment decisions. The market for lung cancer diagnostics and treatment is substantial, with a global market size estimated at billions of dollars annually. Successful commercialization of the Percepta Genomic Atlas could significantly expand Veracyte's revenue streams and market share in the lung cancer diagnostics space. Timeline for launch is estimated within the next 1-2 years, pending regulatory approvals and clinical validation.
• Adoption of Envisia Genomic Classifier for ILD: The Envisia Genomic Classifier aids in diagnosing interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF). The ILD market represents a significant opportunity, as accurate diagnosis is critical for effective treatment. Veracyte's Envisia classifier offers a more precise diagnostic tool compared to traditional methods, potentially leading to increased adoption by pulmonologists. Market penetration is expected to grow steadily over the next 3-5 years.
• Commercialization of LymphMark for Lymphoma Subtyping: Veracyte is developing LymphMark for lymphoma subtyping, which could improve the accuracy and speed of lymphoma diagnosis. The lymphoma diagnostics market is a growing segment within oncology, driven by the increasing incidence of lymphoma and the need for personalized treatment approaches. Successful commercialization of LymphMark could establish Veracyte as a key player in lymphoma diagnostics. Launch is anticipated within the next 2-3 years.
• Geographic Expansion into International Markets: Veracyte currently operates worldwide, but there is significant potential to expand its presence in key international markets, particularly in Europe and Asia. These regions have a growing demand for advanced diagnostic tools and personalized medicine. Strategic partnerships and targeted marketing efforts could drive increased adoption of Veracyte's products in these markets, contributing to revenue growth over the next 5 years.
• Strategic Collaborations and Licensing Agreements: Veracyte has a history of successful collaborations and licensing agreements with companies like Johnson & Johnson, Acerta Pharma, and CareDx. Pursuing additional strategic partnerships could provide access to new technologies, markets, and distribution channels. These collaborations can accelerate the development and commercialization of new diagnostic products and expand Veracyte's overall market reach. Ongoing collaborations are expected to yield new opportunities within the next 2-3 years.

What Opportunities Does VCYT Have?

• Expansion into new geographic markets, particularly in Europe and Asia.
• Development and commercialization of new diagnostic tests for various diseases.
• Strategic acquisitions and partnerships to expand product portfolio.
• Increasing adoption of personalized medicine and genomic testing.

What Threats Does VCYT Face?

• Competition from existing and emerging diagnostic companies.
• Changes in regulatory requirements and reimbursement policies.
• Technological advancements that could render existing products obsolete.
• Economic downturns that could reduce healthcare spending.

What Are VCYT's Competitive Advantages?

• Proprietary Genomic Technologies: Veracyte's genomic sequencing classifiers and assays are protected by patents and trade secrets, providing a competitive advantage.
• Clinical Validation: The company's diagnostic tests have been clinically validated, demonstrating their accuracy and reliability.
• Strategic Collaborations: Partnerships with major players like Johnson & Johnson enhance Veracyte's market reach and credibility.
• Established Market Presence: Veracyte has a strong reputation and established relationships with key customers in the diagnostics market.

What Does VCYT Do?

Veracyte, Inc., founded in 2006 and headquartered in South San Francisco, California, is a global diagnostics company that develops and commercializes genomic tests to improve patient outcomes. Originally named Calderome, Inc., the company rebranded as Veracyte in March 2008, signaling its focus on diagnostic solutions. Veracyte's core business revolves around offering a suite of genomic sequencing classifiers and assays that aid in the diagnosis and treatment of various cancers and pulmonary diseases. Their flagship products include the Afirma Genomic Sequencing Classifier and Xpression Atlas, designed to help physicians determine whether thyroid nodules with indeterminate results are benign, thus avoiding unnecessary surgeries. Other key products include Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis, Prosigna Breast Cancer Assay for breast cancer diagnosis, Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis, Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis, and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte is also actively developing new diagnostic tools, such as the Percepta Genomic Atlas to inform lung cancer treatment decisions, an enhanced Envisia Classifier, the nCounter analysis system, and LymphMark for lymphoma subtyping. The company has established strategic technology licensing and collaboration arrangements with major players like Johnson & Johnson, Acerta Pharma, and CareDx, expanding its reach and capabilities in the diagnostics market.

What Products and Services Does VCYT Offer?

• Develop and commercialize genomic sequencing classifiers and assays.
• Offer diagnostic tests for various cancers, including lung, breast, prostate, and colon cancer.
• Provide diagnostic solutions for interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF).
• Help physicians determine whether thyroid nodules with indeterminate results are benign.
• Inform treatment decisions for lung cancer patients through genomic profiling.
• Develop new diagnostic tools for lymphoma subtyping.
• Establish strategic collaborations with pharmaceutical and diagnostic companies.

How Does VCYT Make Money?

• Generate revenue through the sale of genomic sequencing classifiers and assays.
• Offer diagnostic testing services to hospitals, clinics, and physicians.
• Establish technology licensing and collaboration agreements with other companies.
• Focus on precision medicine by providing actionable insights for personalized treatment decisions.

What Industry Does VCYT Operate In?

Veracyte, Inc. operates within the rapidly evolving biotechnology and diagnostics industry. The market for genomic testing is experiencing significant growth, driven by increasing demand for personalized medicine and more accurate diagnostic tools. The competitive landscape includes companies like Scholar Rock Holding Corporation (SRRK), Apellis Pharmaceuticals, Inc. (APLS), Kiniksa Pharmaceuticals, Ltd. (KNSA), Legend Biotech Corporation (LEGN), and Amicus Therapeutics, Inc. (FOLD), each vying for market share in various segments of the diagnostics and biopharmaceutical space. Veracyte's focus on genomic sequencing classifiers and assays positions it as a key player in providing actionable insights for physicians and patients, contributing to improved healthcare outcomes.

Who Are VCYT's Key Customers?

• Hospitals and medical centers
• Oncologists and pulmonologists
• Pathologists and diagnostic laboratories
• Pharmaceutical companies (through collaborations)
• Patients seeking accurate diagnostic information

Company Profile

Veracyte, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Marc A. Stapley. VCYT has traded publicly since 2013.

F-Score 7/9Financial Health

Veracyte, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 31.35 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 7%Key Financial Metrics

Return on equity for Veracyte, Inc. stands at 6.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.1%, showing how much profit it generates from its asset base. VCYT trades at a trailing price-to-earnings ratio of 39.56, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.31 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.9%, the inverse of the P/E and a quick read on earnings relative to price.

VCYT Valuation & Market Position

With a $4.55B market cap, Veracyte, Inc. sits in the mid-cap segment of the market. Relative to its peer group, VCYT's quantitative score of 99/100 is above the peer average of 51/100.

FY2026 estForward Outlook

Wall Street analysts project Veracyte, Inc. revenue of about $587.2M for fiscal 2026, with EPS near $1.83. The estimate reflects 8 contributing analysts.

VCYT Financials

VCYT Latest News

VCYT Analyst Consensus

VCYT MoonshotScore

VCYT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources